Axsome Therapeutics, Inc. (FRA:19X)

Axsome Therapeutics Statistics

Total Valuation

FRA:19X has a market cap or net worth of EUR 6.59 billion. The enterprise value is 6.49 billion.

Market Cap	6.59B
Enterprise Value	6.49B

Important Dates

The next estimated earnings date is Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	50.41M
Shares Outstanding	n/a
Shares Change (YoY)	+3.38%
Shares Change (QoQ)	+1.17%
Owned by Insiders (%)	1.13%
Owned by Institutions (%)	76.72%
Float	42.50M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	13.77
PB Ratio	104.82
P/TBV Ratio	395.11
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-33.20
EV / Sales	13.42
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-75.15

Financial Position

The company has a current ratio of 1.57, with a Debt / Equity ratio of 2.96.

Current Ratio	1.57
Quick Ratio	1.45
Debt / Equity	2.96
Debt / EBITDA	n/a
Debt / FCF	-2.16
Interest Coverage	-25.65

Financial Efficiency

Return on equity (ROE) is -275.50% and return on invested capital (ROIC) is -42.17%.

Return on Equity (ROE)	-275.50%
Return on Assets (ROA)	-19.79%
Return on Invested Capital (ROIC)	-42.17%
Return on Capital Employed (ROCE)	-63.06%
Revenue Per Employee	586,231
Profits Per Employee	-239,738
Employee Count	683
Asset Turnover	0.91
Inventory Turnover	2.40

Taxes

Income Tax	-745,763
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +40.28% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+40.28%
50-Day Moving Average	112.88
200-Day Moving Average	101.83
Relative Strength Index (RSI)	61.67
Average Volume (20 Days)	32

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.38

Income Statement

In the last 12 months, FRA:19X had revenue of EUR 478.36 million and -195.63 million in losses. Loss per share was -3.97.

Revenue	478.36M
Gross Profit	439.45M
Operating Income	-166.06M
Pretax Income	-196.37M
Net Income	-195.63M
EBITDA	-160.19M
EBIT	-166.06M
Loss Per Share	-3.97

Balance Sheet

The company has 277.23 million in cash and 186.31 million in debt, giving a net cash position of 90.92 million.

Cash & Cash Equivalents	277.23M
Total Debt	186.31M
Net Cash	90.92M
Net Cash Per Share	n/a
Equity (Book Value)	62.84M
Book Value Per Share	1.25
Working Capital	174.77M

Cash Flow

In the last 12 months, operating cash flow was -86.04 million and capital expenditures -374,160, giving a free cash flow of -86.42 million.

Operating Cash Flow	-86.04M
Capital Expenditures	-374,160
Free Cash Flow	-86.42M
FCF Per Share	n/a

Margins

Gross margin is 91.86%, with operating and profit margins of -34.71% and -40.89%.

Gross Margin	91.86%
Operating Margin	-34.71%
Pretax Margin	-41.05%
Profit Margin	-40.89%
EBITDA Margin	-33.49%
EBIT Margin	-34.71%
FCF Margin	n/a

Dividends & Yields

FRA:19X does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.38%
Shareholder Yield	-3.38%
Earnings Yield	-2.97%
FCF Yield	-1.31%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:19X has an Altman Z-Score of 2.8 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.8
Piotroski F-Score	4